Trial Profile
Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety and Immunogenicity When Co-administered With Routine EPI Vaccines in Infants Following Safety Assessment in Children Aged 2-4 Yrs in The Gambia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Sep 2023
Price :
$35
*
At a glance
- Drugs Pneumococcal vaccine (Primary) ; Hib-DTP hepatitis B vaccine (Tritanrix-HepB/Hiberix); Measles virus vaccine live; Pneumococcal 11-valent vaccine conjugate; Pneumococcal 13-valent CRM197 vaccine conjugate; Poliovirus vaccine live oral; Yellow fever vaccine
- Indications Diphtheria; Measles; Pneumococcal infections; Poliomyelitis; Streptococcal infections; Tetanus; Yellow fever
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 08 Apr 2019 Results assessing immunogenicity of the polysaccharide conjugates, and reactogenicity and immunogenicity of co-administered routine vaccines published in the Vaccine
- 04 Apr 2017 Results published in the Vaccine
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.